Penicillamine: The treatment of first choice for patients with Wilson's disease
- 1 July 1999
- journal article
- controversy
- Published by Wiley in Movement Disorders
- Vol. 14 (4) , 545-550
- https://doi.org/10.1002/1531-8257(199907)14:4<545::aid-mds1001>3.0.co;2-u
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Cranial MR imaging in Wilson's disease.American Journal of Roentgenology, 1996
- BRAIN COPPER IN WILSON'S DISEASEThe Lancet, 1987
- Copper: Its Role in the Pathogenesis of Liver DiseaseSeminars in Liver Disease, 1984
- WILSON'S DISEASE AN ANALYSIS OF THE CRANIAL COMPUTERIZED TOMOGRAPHIC APPEARANCES FOUND IN 60 PATIENTS AND THE CHANGES IN RESPONSE TO TREATMENT WITH CHELATING AGENTSBrain, 1981
- The formation and nature of the mixed valence copper-d-penicillamine-chloride cluster in aqueous solution and its relevance to the treatment of Wilson's diseaseJournal of Inorganic Biochemistry, 1979
- ORTHOTOPIC LIVER TRANSPLANTATION FOR WILSON'S DISEASEThe Lancet, 1971
- MANAGEMENT OF PENICILLAMINE NEPHROPATHY IN WILSON'S DISEASE: A NEW CHELATING AGENTThe Lancet, 1969
- EFFECT OF PENICILLAMINE ON FAILURE OF RENAL ACIDIFICATION IN WILSON'S DISEASEThe Lancet, 1968
- Penicillamine, a new oral therapy for Wilson's diseaseThe American Journal of Medicine, 1956
- THE EFFECTS OF B.A.L. IN HEPATOLENTICULAR DEGENERATIONBrain, 1951